Umoja wa Ulaya - Kihispania - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - insulin human - insulinas y análogos para la inyección, de acción intermedia - cats; dogs - para el tratamiento de la diabetes mellitus en perros y gatos para lograr la reducción de la hiperglucemia y la mejora de los signos clínicos asociados a.

Umoja wa Ulaya - Kihispania - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplasias de la mama - agentes antineoplásicos - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Hispania - Kihispania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - gestodeno; etinilestradiol - comprimido recubierto - 0,075 mg/0,02 mg - gestodeno 0,075 mg; etinilestradiol 0,02 mg - gestodeno y estrógeno

Hispania - Kihispania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

madaus gmbh - clormadinona acetato; etinilestradiol - comprimido recubierto con pelÍcula - 2 mg/0,03 mg - clormadinona acetato 2 mg; etinilestradiol 0,03 mg - clormadinona y etinilestradiol

Hispania - Kihispania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teva pharma s.l.u. - anastrozol - comprimido recubierto con pelÍcula - 1 mg - anastrozol 1 mg - anastrozol

Hispania - Kihispania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teva pharma s.l.u. - anastrozol - comprimido recubierto con pelÍcula - 1 mg - anastrozol 1 mg - anastrozol

Hispania - Kihispania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

boehringer ingelheim vetmedica gmbh - insulina zinc protamina - suspensiÓn inyectable - excipientes: sulfato de protamina, glicerol, hidrogenofosfato de sodio heptahidratado, oxido de zinc, acido clorhidrico, hidroxido de sodio (e-524), agua para preparaciones inyectables, fenol - insulina (humana) - gatos

Umoja wa Ulaya - Kihispania - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agentes antineoplásicos - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Hispania - Kihispania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

aristo pharma iberia s.l. - desogestrel - comprimido - 75 microgramos - desogestrel 75 microgramos - desogestrel

Hispania - Kihispania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kern pharma s.l. - levonorgestrel; etinilestradiol - comprimido recubierto con pelÍcula - 0,1 mg/0,02 mg - levonorgestrel 0,1 mg; etinilestradiol 0,02 mg - levonorgestrel y estrógeno